
### [NCIT:C7569](http://purl.obolibrary.org/obo/NCIT_C7569)
**Label:** Thymic Carcinoma

**Subclasses:** [NCIT:C35718](http://purl.obolibrary.org/obo/NCIT_C35718) (Thymic Undifferentiated Carcinoma), [NCIT:C6457](http://purl.obolibrary.org/obo/NCIT_C6457) (Thymic Mucoepidermoid Carcinoma), [NCIT:C6459](http://purl.obolibrary.org/obo/NCIT_C6459) (Thymic Adenocarcinoma), [NCIT:C6458](http://purl.obolibrary.org/obo/NCIT_C6458) (Thymic Adenosquamous Carcinoma), [NCIT:C7998](http://purl.obolibrary.org/obo/NCIT_C7998) (Thymic Lymphoepithelioma-Like Carcinoma), [NCIT:C6463](http://purl.obolibrary.org/obo/NCIT_C6463) (Thymic Sarcomatoid Carcinoma), [NCIT:C6430](http://purl.obolibrary.org/obo/NCIT_C6430) (Thymic Carcinoid Tumor), [NCIT:C27937](http://purl.obolibrary.org/obo/NCIT_C27937) (Thymic Papillary Adenocarcinoma), [NCIT:C6455](http://purl.obolibrary.org/obo/NCIT_C6455) (Thymic Squamous Cell Carcinoma), [NCIT:C6460](http://purl.obolibrary.org/obo/NCIT_C6460) (Thymic Small Cell Carcinoma), [NCIT:C6462](http://purl.obolibrary.org/obo/NCIT_C6462) (Thymic Clear Cell Carcinoma), [NCIT:C6461](http://purl.obolibrary.org/obo/NCIT_C6461) (Thymic Large Cell Neuroendocrine Carcinoma), [NCIT:C45719](http://purl.obolibrary.org/obo/NCIT_C45719) (Thymic Atypical Carcinoid Tumor), 

**Class expressions from DL-Learner:**

- [UBERON:0003846](http://purl.obolibrary.org/obo/UBERON_0003846) (thymus epithelium) 53.33%
- Thing 53.10%
- [UBERON:0002370](http://purl.obolibrary.org/obo/UBERON_0002370) (thymus) 38.69%
- [UBERON:0002370](http://purl.obolibrary.org/obo/UBERON_0002370) (thymus) and (not ([NCIT:C138024](http://purl.obolibrary.org/obo/NCIT_C138024) (Refractory Breast Lymphoma))) 38.69%
- [UBERON:0002370](http://purl.obolibrary.org/obo/UBERON_0002370) (thymus) and (not ([NCIT:C138023](http://purl.obolibrary.org/obo/NCIT_C138023) (Recurrent Breast Lymphoma))) 38.69%
- [UBERON:0002370](http://purl.obolibrary.org/obo/UBERON_0002370) (thymus) and (not ([NCIT:C138022](http://purl.obolibrary.org/obo/NCIT_C138022) (Refractory Testicular Lymphoma))) 38.69%
- [UBERON:0002370](http://purl.obolibrary.org/obo/UBERON_0002370) (thymus) and (not ([NCIT:C138021](http://purl.obolibrary.org/obo/NCIT_C138021) (Recurrent Testicular Lymphoma))) 38.69%
- [UBERON:0002370](http://purl.obolibrary.org/obo/UBERON_0002370) (thymus) and (not ([NCIT:C138020](http://purl.obolibrary.org/obo/NCIT_C138020) (Refractory Central Nervous System Lymphoma))) 38.69%
- [UBERON:0002370](http://purl.obolibrary.org/obo/UBERON_0002370) (thymus) and (not ([NCIT:C138019](http://purl.obolibrary.org/obo/NCIT_C138019) (Recurrent Central Nervous System Lymphoma))) 38.69%
- [UBERON:0002370](http://purl.obolibrary.org/obo/UBERON_0002370) (thymus) and (not ([NCIT:C138014](http://purl.obolibrary.org/obo/NCIT_C138014) (Refractory B-Cell Lymphoma, Unclassifiable, with Features Intermediate between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma))) 38.69%
- [UBERON:0002370](http://purl.obolibrary.org/obo/UBERON_0002370) (thymus) and (not ([NCIT:C138013](http://purl.obolibrary.org/obo/NCIT_C138013) (Recurrent B-Cell Lymphoma, Unclassifiable, with Features Intermediate between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma))) 38.69%
- [UBERON:0002370](http://purl.obolibrary.org/obo/UBERON_0002370) (thymus) and (not ([NCIT:C137862](http://purl.obolibrary.org/obo/NCIT_C137862) (Refractory Pancreatic Neuroendocrine Carcinoma))) 38.69%
- [UBERON:0002370](http://purl.obolibrary.org/obo/UBERON_0002370) (thymus) and (not ([NCIT:C137857](http://purl.obolibrary.org/obo/NCIT_C137857) (Refractory Anal Carcinoma))) 38.69%
- [UBERON:0002370](http://purl.obolibrary.org/obo/UBERON_0002370) (thymus) and (not ([NCIT:C137839](http://purl.obolibrary.org/obo/NCIT_C137839) (Pleomorphic Lobular Breast Carcinoma In Situ))) 38.69%
- [UBERON:0002370](http://purl.obolibrary.org/obo/UBERON_0002370) (thymus) and (not ([NCIT:C137645](http://purl.obolibrary.org/obo/NCIT_C137645) (Cutaneous Melanoma by AJCC v8 Stage))) 38.69%


